Skip to main content
OpenTrials
Completed

NCT Number: NCT03756220

Ascorbic Acid and Thiamine Effect in Septic Shock

The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Emergency Medicine, Seoul National University Bundang Hospital,, Seongnam-si, Gyeonggi-do, South Korea

Loading trial locations.

About this study

Sepsis is a complex disease involving life-threatening organ dysfunction caused by a dysregulated host response to infection and is still associated with unacceptably high mortality. Sepsis management should be undertaken as a medical emergency and focused on timely intervention, including early identification and treatment of infection through appropriate antimicrobial therapy and source control when applicable as well as reversing hemodynamic instability through fluid resuscitation and vasopressor use if necessary. Despite these supportive therapies, morbidity and mortality have remained high, suggesting the need for adjuvant therapies for inflammatory and oxidative stress in patients with sepsis; however, no agents have been proven to definitely improve survival.

Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important as a cofactor/co-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin. Recently, several clinical trials have reported the positive effects of vitamin C on outcomes in sepsis or septic shock. During sepsis, vitamin C prevents neutrophil-induced lipid oxidation and protects against the loss of the endothelial barrier. Early intravenous supplementation is therefore needed to limit loss of microcirculation and oxidation of lipids. Thiamine is also a key cofactor for glucose metabolism, the generation of ATP (adenosine triphosphate), and the production of NADPH. Considering acute consumption in the hypermetabolic state, thiamine supplementation might be a reasonable therapeutic adjunct for patients with sepsis and was added to reduce the risk of renal oxalate crystallization. These findings led to a recent before-and-after study showing that treatment of sepsis with a combination of vitamin C, hydrocortisone, and thiamine prevented organ dysfunction and reduced the mortality rate.

The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (> 18 years)
  • Septic shock: sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure ≥65 mm Hg and a serum lactate level >2 mmol/L despite adequate volume resuscitation. Sepsis is defined as clinically suspected or confirmed infection with acute organ failure identified as an acute change in total SOFA score with 2 points or more.

Exclusion criteria

  • Transferred patients from other hospitals after application of vasopressors or mechanical ventilation
  • Patients who signed a "Do not attempt resuscitation" order or who had set limitations on invasive care
  • Patients who have a terminal, unresponsive illness and survival discharge is not expected (metastatic terminal cancer, etc.)
  • Patients who experienced cardiac arrest before enrollment or when death is anticipated within 24 hours despite maximal treatment
  • Patients who take more than 1g of Vitamin C per day before enrollment or who take supplemental thiamine
  • Pregnant woman
  • Known Glucose-6-phosphate dehydrogenase deficiency
  • Patients with a history of hypersensitivity to vitamin C or thiamine
  • Known Mediterranean anemia
  • Known hyperoxaluria
  • Known cystinuria
  • Acute gout attack
  • Known oxalate renal stone
  • Patients who meet the inclusion criteria 24 hours after emergency department arrival or when enrollment is delayed more than 24 hours after diagnosis of septic shock
  • Inability or refusal of a subject or legal surrogate to give informed consent

Treatment and study plan

Combination therapy of vitamin C and thiamine

Drug

Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days

Other names: Ascorbic Acid Injection, Thiamine Injection

Normal saline solution

Drug

Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days

Other names: 0.9% NaCl

Primary outcomes

  1. Delta Sequential Organ Failure Assessment (SOFA) score

    Time frame: Enrollment to 72 hours

    72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours)

Secondary outcomes

  1. 28-day mortality

    Time frame: Day 28

    The number of participants who did not survive until Day 28 will be compared between the treatment and the control group

  2. 7-day mortality (early death)

    Time frame: Day 7

    The number of participants who did not survive until Day 7 will be compared between the treatment and the control group

  3. 90-day mortality

    Time frame: Day 90

    The number of participants who did not survive until Day 90 will be compared between the treatment and the control group

  4. Time to death

    Time frame: Enrollment to Day 28

    Days until death

  5. In-hospital death

    Time frame: Up to 12 weeks

    The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group

  6. Intensive care unit death (ICU) death

    Time frame: Up to 12 weeks

    The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group

  7. Time to Shock reversal

    Time frame: Enrollment to Day 14

    Days from enrollment to shock reversal until Day 14. Shock reversal is defined as discontinuation of all vasopressors and mean arterial pressure is maintained at 60 mmHg or more for more than 24 hours.

  8. Vasopressor free days

    Time frame: Enrollment to Day 14

    Days not receiving any vasopressor

  9. Ventilator free days

    Time frame: Enrollment to Day 14

    Days not receiving mechanical ventilation

  10. Ventilator duration

    Time frame: Up to 12 weeks

    Days receiving mechanical ventilation during hospital stay

  11. Renal replacement therapy (RRT) free days

    Time frame: Enrollment to Day 14

    Days not receiving Renal replacement therapy

  12. New use of renal replacement therapy (RRT)

    Time frame: Up to 12 weeks

    The number of participants who receive RRT during hospital stay will be compared between the treatment and the control group

  13. New onset or aggravation of acute kidney injury (AKI)

    Time frame: Enrollment to Day 14

    The number of participants who suffer from new onset or aggravation of AKI will be compared between the treatment and the control group

  14. Length of ICU stay

    Time frame: Up to 12 weeks

    Number of days in the ICU during hospital admission

  15. ICU free day

    Time frame: Enrollment to Day 14

    Days not being in the ICU

  16. Length of hospital stay

    Time frame: Up to 12 weeks

    Number of days in the hospital during hospital admission

Other outcomes

  1. CRP (C-reactive protein) change during initial 72 hours

    Time frame: Enrollment to 72 hours

    72-hour change in CRP (%)

  2. Procalcitonin change during initial 72 hours

    Time frame: Enrollment to 72 hours

    72-hour change in procalcitonin (%)

  3. Dose of vasopressor at 24-hour

    Time frame: Enrollment to 24 hours

    Norepinephrine equivalent dose at 24 hours from enrollment

  4. Dose of vasopressor at 48-hour

    Time frame: Enrollment to 48 hours

    Norepinephrine equivalent dose at 48 hours from enrollment

  5. Dose of vasopressor at 72-hour

    Time frame: Enrollment to 72 hours

    Norepinephrine equivalent dose at 72 hours from enrollment

  6. Maximum dose of vasopressor during initial 72 hours

    Time frame: Enrollment to 72 hours

    Maximum norepinephrine equivalent dose during initial 72 hours

Sponsors and collaborators

Lead sponsor

Tae Gun Shin

Other

Collaborators

  • National Research Foundation of Korea

Registry information

Official study title

Combination Therapy of Vitamin C and Thiamine for Septic Shock: Multi-center, Double-blinded, Randomized, Controlled Study

Acronym: ATESS

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Nov 28, 2018
Registry last updated
Oct 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.